RPG Life Sciences Q1 FY27 results: Revenue up 16% YoY to Rs 195.69 cr

Exceptional ItemResults View source PDF Explain this filing

RPGLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.0%Reaction day

₹2906.00

prior close

₹2950.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.5%-2.5% vs market

Pharmaceuticals peers, median of 160sector+0.8%-2.8% vs sector

On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 2.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.5

10m

-3.4

15m

-4.9

30m

-1.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.0+0.5-2.5+0.8-2.8

Next day

-4.1-0.1-4.0+0.0-4.1

-4.7+1.0-5.7+0.1-4.8

-5.1+2.3-7.4+0.6-5.7

-6.0+2.8-8.7+1.0-7.0

-6.2+4.1-10.3+0.6-6.9

-8.8+4.5-13.3+1.6-10.4

15d

-8.8+4.8-13.6+0.5-9.3

-9.0+6.4-15.4+2.1-11.1

+6.8+5.5+1.3+3.3+3.5

+3.5-1.7+5.3-2.2+5.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q1 FY27 (ended June 30, 2026) standalone and consolidated results. Revenue from operations grew about 16% YoY to Rs 195.69 cr from Rs 168.92 cr. Standalone PAT rose modestly to Rs 30.57 cr from Rs 29.90 cr. EPS at Rs 18.49 versus Rs 18.08. No exceptional items this quarter. Transfer of API division to wholly owned subsidiary RPG Active Pharma Ltd is pending approvals.

Likely market impact

Steady revenue growth, margins stable. API division restructuring awaiting approvals may reshape business. Clean auditor review.